News
Zuellig Pharma to distribute imdur in eight markets for Topridge Pharma
Zuellig Pharma and TopRidge Pharma Limited have signed a deal that will see Zuellig Pharma distribute Imdur, a mature medicine for the prevention of angina in patients with heart disease, in eight markets across the region. ...
News
Amgen To Present At The Morgan Stanley Global Healthcare Conference
Amgen will present at the Morgan Stanley Global Healthcare Conference at 10:30 a.m. ET on Wednesday, Sept. 14, 2016, in New York City. Robert A. Bradway, chairman and chief executive officer at Amgen, will present at the conference. ...
News
Teva to Present at the Wells Fargo 2016 Healthcare Conference
Teva Pharmaceutical Industries Ltd will host a live audio webcast at the Wells Fargo Healthcare Conference. Eyal Desheh will present on Wednesday, September 7, 2016 at 1:10 PM ET. What:ย Teva Presentation at the Wells Fargo 2016...
News
Teva to Host Generic Medicines Business Overview on September 9, 2016
Teva Pharmaceutical Industries Ltd. announced that it will host a conference call and live webcast along with a slide presentation on Friday, September 9, 2016 at 8:00 a.m. ET to communicate an overview of the future prospects of Teva...
News
TG Therapeutics Announces TG-1101 for the Treatment of Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder
TG Therapeutics, Inc. announced that the U.S. FDA has granted orphan drug designation for TG-1101 (ublituximab) the Companyโs novel, glycoengineered anti-CD20 monoclonal antibody, for the treatment of patients with neuromyelitis optica (NMO) and neuromyelitis optica spectrum disorder (NMOSD). ...
News
Biotie: BTT1023 receives Orphan Drug Designation in the United States
The United States Food and Drug Administration (FDA) has granted Orphan Drug Designation in the United States for Biotie's BTT1023 drug candidate for the treatment of primary sclerosing cholangitis (PSC). PSC is a chronic and progressive fibrotic liver disease...
News
Mylan Invalidates Two of Teva’s Copaxoneยฎ 40 mg/mL Patents Via U.S. Patent and Trademark Office
Mylan N.V. announced that the U.S. Patent and Trademark Office (PTO) has ruled in favor of Mylan in its inter partes review (IPR) proceeding and found all claims of two related Copaxoneยฎ 40 mg/mL patents to be unpatentable. The...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.















